AbbVie Can't Trim Report In Testosterone Replacement MDL
By Hannah Meisel (January 3, 2017, 9:23 PM EST) -- An Illinois federal judge overseeing multidistrict litigation over heart health risks and injuries allegedly caused by testosterone replacement therapy drugs refused Tuesday to trim an expert report that supports claims against drugmaker AbbVie Inc.
U.S. District Judge Michael Kennelly entered his notice the day before the deposition of Dr. B. Bud Gerstman, the doctor who wrote the rebuttal report for the plaintiffs' steering committee in the case. AbbVie had requested Gerstman's supplemental report, dated Dec. 26, be trimmed to only the agreed-upon scope of scientific articles written pertaining to testosterone replacement therapy and heart health. Gerstman, a professor at San Jose...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!